03 Profile
Vital Signsby Bridgehead
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Dorte X. Gram: no licensed photograph is held, so the sector leader plate is shown instead.
Sector leader
Dorte X. Gram
founder and CSO of Pila Pharma
1
0
0
0
0
0
0
0
0
0
Feb 2026MarAprMayJuneJulyAugSeptOctNovto date
1
press citation on 1 topic since 12 Feb 2026 · last quoted 12 Feb 2026
02 Quoted on · 1 of 29 topics
Dorte X. Gram: key facts
- Kind of voice
- Sector leader
- Role
- founder and CSO of Pila Pharma
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 12 Feb 2026
04 The signal · where Dorte X. Gram sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Dr Danielle FreedmanClinicianConsultant Chemical Pathologist & Deputy Medical Director1
- 25=Sneha PatelAcademicClinical Director for Haematology1
- 25=Dorte X. GramSector leaderfounder and CSO of Pila Pharma1
- 25=Hans QuidingAcademicPila Pharma's scientific expert in pain management1
- 25=Dr. Stanley CrookeAcademicFounder of Ionis Pharmaceuticals, CNBC Advisory Board member1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Dorte X. Gram has said
By outlet · linked articles
- biostock.se1
Where Dorte X. Gram has been quoted
- 01Pila Pharma activates lucrative orphan drug trackbiostock.se · 12 Feb 2026
Verbatim
“I'm very pleased that we can now actively start preparing to study the effect of our lead candidate in erythromelalgia. Patients often contact me, as they have heard of PILA's ambitions to develop a good treatment, that could ease their daily sufferings.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.